Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Thursday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on ESPR. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $1.62 on Thursday. The company’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $2.07. Esperion Therapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $3.94. The stock has a market capitalization of $320.52 million, a P/E ratio of -2.53 and a beta of 1.04.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Summit Financial LLC raised its position in Esperion Therapeutics by 18.2% during the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 7,150 shares during the last quarter. Foundations Investment Advisors LLC lifted its position in Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares during the period. Invesco Ltd. lifted its position in Esperion Therapeutics by 15.5% during the fourth quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock valued at $215,000 after purchasing an additional 13,101 shares during the period. Two Sigma Advisers LP grew its position in Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after purchasing an additional 16,100 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Esperion Therapeutics by 15.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 16,404 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.